Literature DB >> 24532913

Livedoid vasculopathy managed with hyperbaric oxygen therapy.

Sourabh Bhutani1, Rohit Verma2, George Verghese3.   

Abstract

Livedoid vasculopathy is an uncommon condition resulting in painful lower extremity ulceration and scarring. This condition presents as purpuric macules and papules that progress to painful, irregular ulcers of the lower legs and dorsal feet. These ulcerations are often recurrent and chronic with spontaneous remissions and exacerbations that may be seasonal. The first case, a 22-year-old female presented with three-year history of recurrent multiple non-healing ulcers involving feet and ankles. The ulcers were associated with severe debilitating pain and paraesthesia, as a result of which she was unable to walk without support. Patient was administered HBOT at pressure of 2.5ATA for 1 h daily, six days a week. After ten sittings of HBOT, patient reported a drastic reduction in the pain along with reduction in the dose of analgesic by half and a definite improvement in her walking. The second case was a 49-year-old male who also had history of recurrent ulceration on the dorsum of feet and ankles associated with severe pain. With HBOT, the patient felt an improvement in pain and ambulation by the 8th sitting and complete relief from pain by the 17th sitting. HBOT is a recognized modality of treatment of various problem wounds and non-healing ulcers due to various etiologies. The above two cases show that it can be a useful treatment modality for livedoid vasculopathy where other treatment modalities have failed and therefore could be given to a larger number of patients in hospitals where it is available.

Entities:  

Keywords:  Atrophie blanche; Hyperbaric oxygenation; Livedoid vasculopathy

Year:  2012        PMID: 24532913      PMCID: PMC3862953          DOI: 10.1016/j.mjafi.2012.01.002

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  6 in total

Review 1.  Hyperbaric oxygen: its uses, mechanisms of action and outcomes.

Authors:  A L Gill; C N A Bell
Journal:  QJM       Date:  2004-07

2.  Role of hyperbaric oxygen therapy in the management of lower extremity wounds.

Authors:  D Mathieu
Journal:  Int J Low Extrem Wounds       Date:  2006-12       Impact factor: 2.057

3.  Livedoid vasculopathy: long-term follow-up results following hyperbaric oxygen therapy.

Authors:  W-H Juan; Y-S Chan; J C Lee; L-C Yang; H-S Hong; C-H Yang
Journal:  Br J Dermatol       Date:  2006-02       Impact factor: 9.302

4.  Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study.

Authors:  E Faglia; F Favales; A Aldeghi; P Calia; A Quarantiello; G Oriani; M Michael; P Campagnoli; A Morabito
Journal:  Diabetes Care       Date:  1996-12       Impact factor: 19.112

5.  A case of livedoid vasculopathy in a 22-year-old man.

Authors:  Aimee Leonard; Miriam Keltz Pomeranz; Andrew G Franks
Journal:  J Drugs Dermatol       Date:  2004 Nov-Dec       Impact factor: 2.114

6.  Intractable livedoid vasculopathy successfully treated with hyperbaric oxygen.

Authors:  C-H Yang; H-C Ho; Y-S Chan; L-B Liou; H-S Hong; L-C Yang
Journal:  Br J Dermatol       Date:  2003-09       Impact factor: 9.302

  6 in total
  3 in total

Review 1.  Is there a role for hyperbaric oxygen therapy in the treatment of refractory wounds of rare etiology?

Authors:  Pasquale Longobardi; Klarida Hoxha; Michael H Bennett
Journal:  Diving Hyperb Med       Date:  2019-09-30       Impact factor: 0.887

Review 2.  Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management.

Authors:  Asli Bilgic; Salih Ozcobanoglu; Burcin Cansu Bozca; Erkan Alpsoy
Journal:  Int J Womens Dermatol       Date:  2021-09-02

Review 3.  From dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy.

Authors:  Paulo Ricardo Criado; Hélio Amante Miot; Thais Prota Hussein Pincelli; Alexandre Todorovic Fabro
Journal:  Dermatol Ther       Date:  2020-11-30       Impact factor: 3.858

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.